Skip to main content
News
 

MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter

 

MASON, Ohio --(BUSINESS WIRE)--Sep. 6, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education

 

MASON, Ohio --(BUSINESS WIRE)--Aug. 16, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the

 

MASON, Ohio --(BUSINESS WIRE)--Aug. 2, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results.

 

MASON, Ohio --(BUSINESS WIRE)--Jul. 20, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two

 

MASON, Ohio --(BUSINESS WIRE)--Jul. 12, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second

 

Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio --(BUSINESS WIRE)--Jun. 7, 2022-- AtriCure, Inc.

 

MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief

 

MASON, Ohio --(BUSINESS WIRE)--May 3, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results.

 

New clamp is designed to improve efficiency of concomitant ablation procedures MASON, Ohio --(BUSINESS WIRE)--Apr. 12, 2022-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and

 

MASON, Ohio --(BUSINESS WIRE)--Apr. 11, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter

 

MASON, Ohio ,--(BUSINESS WIRE)--Feb. 15, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021

 

MASON, Ohio --(BUSINESS WIRE)--Feb. 8, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and

 

MASON, Ohio --(BUSINESS WIRE)--Feb. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 11 th Annual SVB Leerink Global

 

MASON, Ohio --(BUSINESS WIRE)--Jan. 25, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth